PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Novacyt (ALTERNEXT:ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces an update to its launch of NOVAprep® in China through its partnership with Leica Biosystems.
The Company is pleased to announce the launch of its new generation NOVAprep® instrument for the analysis of Novaprep samples which is being manufactured in China specifically for the Chinese market.
Novacyt has been working for more than two years with a Chinese-based, high-end specialist instrument manufacturer to develop a new NOVAprep® platform for its next generation product. This partnership will also provide distribution, logistics and after-sales support in order to take full advantage of the large but demanding Chinese market.
The new instrument includes a significant number of operational benefits for laboratory users and provides laboratories with a new level of automation and instrumentation. The instrument was recently showcased at the Annual Meeting of the Chinese Society of Pathology (CSP) by Leica Biosystems in Hangzhou, where more than 1,200 Chinese pathologists and medical laboratory scientists were assembled. Novacyt reported recently that it has started to receive purchase orders from Leica and early feedback suggests the new generation NOVAprep® platform is generating significant customer interest.
By the end of the year Novacyt expects to have attended more than 20 separate regional meetings and customer demos as it launches its new generation NOVAprep® instrument across the country which the Company expects will provide a strong platform for revenue growth in 2016.
Graham Mullis, Group CEO of Novacyt, commented: “We have been investing heavily in the Chinese market both with the pre-launch support of Leica Biosystems since signing our distribution partnership earlier in the year, and also through the establishment and design of the new instrumentation with our new manufacturer based in China. Having personally spent a number of years building a successful business in the Asia Pacific region, I am particularly pleased with the progress Novacyt has made in identifying and partnering with a robust and high quality instrument manufacturer. In my view, local manufacturing and distribution is essential to effectively support the huge but challenging opportunity of the Chinese market. In this respect, the Company has made strong progress during 2015 and is now well placed to capitalise on the opportunity in China for 2016. “
- Ends –